Medicare prescription drug cost, prescriptions and prescribers, 2024
Medicare cost, 2024
$5.29B
+18.8% from 2023
Prescriptions
6.2M
$847.00 per claim
Patients
1.3M
237,439 prescribers
Total spending, 2024
$5.29B
$4,172.39 per patient
Medicare prescription drug plans paid $5.29B for Trelegy Ellipta in 2024, for 6,248,740 prescriptions and refills to 1,268,461 patients (up 18.8% from 2023). The average cost per claim was $847.00.
Florida had the highest Medicare cost for Trelegy Ellipta in 2024: $428.0M for 473,878 claims, followed by New York ($353.5M).
Jorge Sanchez-Masiques, pulmonary disease in Miami, FL, had the highest Medicare cost for Trelegy Ellipta in 2024: 3,564 claims costing $2.4M.
Trelegy Ellipta is made by GSK plc (GSK), listed in the Medicare spending data as Glaxosmithkline.
All plans and makers
Where the prescribers practice, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| Jorge Sanchez-Masiques Miami, FL | Pulmonary Disease | 3,564 | 683 | $2.4M |
| Kaiser Toosy New Haven, CT | Pulmonary Disease | 2,514 | 466 | $2.3M |
| Jason B Karp |
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 175,214 | 3,925,466 | 833,805 | $3.34B |
| 2023 | 208,099 | 5,007,613 | 1,049,967 | $4.45B |
| 2024 | 237,439 | 6,248,740 | 1,268,461 | $5.29B |
More drugs: top Medicare drugs by cost and the Prescriptions tab.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
| Pulmonary Disease |
| 1,722 |
| 533 |
| $2.0M |
| Michael A Imevbore New Haven, CT | Pulmonary Disease | 1,541 | 443 | $1.9M |
| Ernesto Mejia Morristown, TN | Pulmonary Disease | 2,304 | 529 | $1.8M |
| Rajesh Agrawal Pinellas Park, FL | Pulmonary Disease | 2,210 | 524 | $1.7M |
| Ladly Abraham Conway, AR | Pulmonary Disease | 2,033 | 389 | $1.6M |
| Ahmed S Bhatti Granbury, TX | Pulmonary Disease | 2,065 | 434 | $1.6M |
| Morgan G Miller Rocky Mount, NC | Nurse Practitioner | 1,775 | 385 | $1.6M |
| Elizabeth M Kluka Kalamazoo, MI | Critical Care (Intensivists) | 2,139 | 383 | $1.6M |
| Ashesh D Desai Conroe, TX | Pulmonary Disease | 1,298 | 369 | $1.5M |
| Rafael A Martinez Tampa, FL | Pulmonary Disease | 2,001 | 448 | $1.5M |
| Fernando L Martinez Catinchi Hialeah, FL | Pulmonary Disease | 2,264 | 708 | $1.5M |
| Ajay D Deshpande Terre Haute, IN | Pulmonary Disease | 1,736 | 404 | $1.4M |
| Hoang T Le Fountain Valley, CA | Pulmonary Disease | 1,648 | 283 | $1.4M |
| Richard A Miller Newark, NJ | Pulmonary Disease | 1,874 | 359 | $1.4M |
| Lohaliz Bobe Port Charlotte, FL | Pulmonary Disease | 1,405 | 312 | $1.4M |
| Walid F Tanyous Venice, FL | Pulmonary Disease | 979 | 340 | $1.3M |
| Gary R Schafer Forest City, NC | Pulmonary Disease | 1,703 | 314 | $1.3M |
| Ahmad M Ibrahimbacha Cleveland, TN | Pulmonary Disease | 1,836 | 330 | $1.3M |
| Alec J Steils Waterloo, IA | Nurse Practitioner | 1,456 | 310 | $1.3M |
| Stephen G Basheda Pittsburgh, PA | Pulmonary Disease | 1,833 | 312 | $1.3M |
| Gaurav Sangwan Springfield, IL | Pulmonary Disease | 1,618 | 267 | $1.3M |
| Rohit G Patel Anniston, AL | Pulmonary Disease | 1,766 | 325 | $1.3M |
| Wendi Shaffmaster Richmond, IN | Nurse Practitioner | 1,531 | 289 | $1.3M |
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Glaxosmithkline GSK | 6,250,872 | $5.29B |